Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 OC3.2 | DOI: 10.1530/endoabs.99.OC3.2

ECE2024 Oral Communications Oral Communications 3: Adrenal and Cardiovascular Endocrinology | Part I (6 abstracts)

Copeptin and asymptomatic arterial disorder in patients with type 2 diabetes, a cross-sectional study

Lee Ti Davidson 1 , Jan Engvall 2 , Simona Chisalita 3 , Carl Johan Östgren 4 & Fredrik Nyström 2


1Linköping University, Department of Emergency Medicine and Department of Biomedical and Clinical Sciences, Linköping, Sweden; 2Linköping University, Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping, Sweden; 3Linköping University, Department of Endocrinology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; 4Linköping University, Division of Prevention, Rehabilitation and Community Medicine, Department of Health, Medicine and Caring Sciences, Linköping, Sweden


Background: Individuals with diabetes are at higher risk for developing arterial disorders. The toe-brachial index (TBI) is associated with peripheral vascular disease, and aortic pulse-wave velocity (aPWV) is currently the gold standard for assessing arterial stiffness. High concentrations of plasma arginine vasopressin (AVP) preferentially stimulate V1a receptors, which affect the vascular bed and may contribute to cardiovascular (CV) complications. Copeptin, a more stable peptide of AVP, is co-secreted from the pituitary gland in equimolar amounts to AVP upon hemodynamic, osmotic, and other stress-related stimuli. Elevated levels of copeptin are potentially linked to vascular dysfunction.

Objective: To analyze the association of copeptin to TBI and aPWV as a marker of arterial disorder in patients with type 2 diabetes mellitus (T2D).

Methods: A cross-sectional analysis was conducted on 681 patients from the epidemiological study CARDIPP (Cardiovascular Risk Factors in Patients with Diabetes – a Prospective Study in Primary Care; ClinicalTrials.gov identifier NCT01049737) with data on copeptin, TBI, and aPWV. The relationship between the conventional cardiovascular risk factors and copeptin with TBI and aPWV were examined, respectively. Pearson correlation analysis and linear regression analyses were used.

Results: Copeptin correlated to TBI (r=-0.086, P=0.027) and aPWV (r=0.143, P<0,001). Copeptin was also negatively associated with TBI (β=-0.093, P=0.027) and aPWV (β=0.121, P=0.004) independently of age, sex, diabetes duration, BMI, smoking, previous cardiovascular diseases, HbA1c, HDL cholesterol, and estimated glomerular filtration rate.

Conclusion: Copeptin is independently associated with TBI and aPWV. Copeptin may play an important role in the development of arterial disorders. Measuring copeptin levels may be a simpler method and more efficient way to identify individuals at risk for arterial disorders compared to current methods such as TBI and aPWV.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.